AstraZeneca PLC (LON: AZN) to Sell the rights of Crestor, related medicines in Europe

  • December 01, 2020 04:20 PM GMT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2207 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

AstraZeneca PLC (LON: AZN) to Sell the rights of Crestor, related medicines in Europe

AstraZeneca PLC (LON: AZN) will be selling its rights of Crestor and some related medicines to Germany-based Grünenthal GmbH in more than 30 countries of Europe except the UK and Spain. The deal is worth up to $350 million.

AstraZeneca will continue manufacturing and supplying Crestor to Grünenthal during the transition period and selling it in countries such as China, Japan, North America, and others.

Crestor medicine

Crestor is a statin, lipid-lowering medicine that is used in the treatment of dyslipidemia and high cholesterol. The medicine is also helpful in the prevention of heart attacks and strokes. Crestor has been certified in more than 100 countries as a medicine for regulating lipid. The lipid modifying effects are produced by Crestor in two ways -- by blocking an enzyme in the liver or by increasing the breakdown of already existing cholesterol in the blood.

The Deal

Crestor had generated $136 million of product sales and $98 million of profit before tax in 2019.

The divestment deal will provide AstraZeneca with an upfront, non-contingent payment of $320 million from Grünenthal, which might also make future milestone payments of up to $30 million. The cash proceeds, which will form a part of AstraZeneca's other operating income and expense in the financial statement, will be used for general corporate purposes.

The divestment is expected to see a final closure in the first quarter of 2021, based on customary closing conditions and regulatory clearances. There will be no impact of the divestment in the financial outlook of the company for this year.

Ruud Dobber, AstraZeneca BioPharmaceuticals Business Unit’s Executive Vice President, said that Grünenthal is well-positioned to ensure availability of Crestor for patients across Europe. In the past, Grünenthal had acquired the rights to various established medicines of AstraZeneca. This agreement would enable the development of innovative and new treatments, he added.

Also Read: AstraZeneca (AZN) Sells the rights of Two drugs to Cheplapharm for US$400 million

At 12:42 PM, the shares of AstraZeneca PLC were trading at GBX 7,899.00, moving up by 1.20 per cent from its last day close of GBX 7,805.00.

AstraZeneca’s Vaccine Candidate

The UK-based biopharmaceutical company has been in the news for developing the vaccine for combating SARS-CoV-2, in association with the University of Oxford. The vaccine is in its final stage of clinical trials.

It was the third developer to provide their early clinical results after Moderna Inc. and Pfizer Inc.-BioNTech SE partnership.

Recently, the pharma major released the results of its vaccine candidate’s interim analysis of clinical trials in the UK and Brazil, showing positive results, proving highly effective. When the half dose of the potential vaccine was given, followed by a full dose in a month’s interval, it showed 90 per cent efficacy. Whereas, when two full doses were given after an interval of one month, it showed 62 per cent efficacy. Average efficacy of 70 per cent was reported on combining the analysis from both dosing regimens.

AstraZeneca will now be moving ahead for the regulatory submission of the data to authorities around the world.







The website is a service of Kalkine Media Ltd (Kalkine Media), Company Number 12643132. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK